Full Text: bit.ly/2xufwZQ
Critically, our findings suggest for the first time that targeting BRAFWT/V600E and CDK4/6 represents a novel therapeutic strategy to treat vemurafenib-resistant or vemurafenib-naïve radioiodine-refractory BRAFWT/V600E-PTC. This combined therapy could prevent selection and expansion of aggressive PTC cell sub-clones with intrinsic resistance, targeting tumor cells either with primary or secondary resistance to BRAFV600E inhibitor.
Facebook - bit.ly/2xznxjV
Twitter - bit.ly/2xzWvsu
LinkedIn - bit.ly/2xzJ6kc
Pintrest - bit.ly/2xzX8SS
Reddit - bit.ly/2hoxI0N
www.Oncotarget.com
